Cited by 102Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesChronic Myeloid Leukemia Treatments

The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome

Prebet, Thomas, Lhoumeau, Anne-Catherine, Arnoulet, Christine, Aulas, Anaïs, Marchetto, Sylvie, Audebert, Stéphane, Puppo, Francesca, Chabannon, Christian +10 more·2010·Blood

Abstract

The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. It plays a major role during embryogenesis and epithelial tissue organization. Here we found that PTK7 is also expressed in normal myeloid progenitors and CD34+ CD38− bone marrow cells in humans. We performed an immunophenotyping screen on more than 300 patients treated for hematologic malignancies. We demonstrated that PTK7 is expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. Patients with PTK7-positive AML are more resistant to anthracycline-based frontline therapy with a significantly reduced leukemia-free survival in a multivariate analysis model. In vitro, expression of PTK7 in cultured leukemia cells promotes cell migration, cell survival, and resistance to anthracycline-induced apoptosis. The intracellular region of PTK7 is required for these effects. Furthermore, we efficiently sensitized primary AML blasts to anthracycline-mediated cell death using a recombinant soluble PTK7-Fc protein. We conclude that PTK7 is a planar cell polarity component expressed in the myeloid progenitor compartment that conveys promigratory and antiapoptotic signals into the cell and that represents an independent prognosis factor of survival in patients treated with induction chemotherapy.

Integrity signals

Registry

Crossref · 10.1182/blood-2010-01-262352

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PTK7 is upregulated in many common cancers including T-ALL and is a potential biomarker of T-ALL.

    “PTK7 is a transmembrane receptor that is upregulated in many common cancers including acute T-lymphocytic leukemia (T-ALL) and is a potential biomarker of T-ALL.259”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [259]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Prebet, T., Lhoumeau, A.-C., Arnoulet, C., Aulas, A., Marchetto, S., Audebert, S., Puppo, F., Chabannon, C., Sainty, D., Santoni, M.-J., Sebbagh, M., Summerour, V., Huon, Y., Shin, W.-S., Lee, S.-T., Esterni, B., Vey, N., & Borg, J.-P.
Affiliations
  • Inserm U891, Centre de Recherche en Cancérologie de Marseille, Marseille, France;
  • Inserm (FR)
  • Institut Paoli-Calmettes (FR)
  • Yonsei University (KR)
Venue
Blood
Published
2010-09-30
Volume
116
Issue
13
Pages
2315-2323
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2002387564
Cited by
102
References
42
Citations by year
2026: 5 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 11 · 2018: 6 · 2017: 5 · 2016: 6 · 2015: 10 · 2014: 8 · 2013: 5 · 2012: 12
FWCI
4.41
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
Keywords
PTK7, acute myeloid leukemia, planar cell polarity, receptor tyrosine kinase, anthracycline resistance, chemotherapy response, leukemia-free survival, prognostic factors, cell migration, apoptosis resistance, myeloid progenitor cells, granulocytic differentiation
MeSH terms
Antibiotics, Antineoplastic, Base Sequence, Cell Movement, Humans, Prognosis, Leukemia, Myeloid, Acute, Cell Adhesion Molecules, Immunophenotyping, Cell Polarity, Treatment Outcome, Apoptosis, DNA Primers, HL-60 Cells, Anthracyclines, Drug Resistance, Neoplasm, Jurkat Cells, K562 Cells, U937 Cells, Cytogenetic Analysis, Receptor Protein-Tyrosine Kinases, Cell Line, Tumor, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review